{"schema":"sb.node.v1","id":"sb:e/7e334b5071e5b4486106b1fd","kind":"entity","label":{"text":"kras","locale":"en"},"identity":{"anchor":"label:en:kras","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-29T21:52:40.283342+00:00","releaseId":"sb-e7a81eb166c0","snapshot":"deploy 0920942a6e77ad66e9bb1404f3a6c2be0c67f8a2"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":481,"separatePublishers":183,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":0.798,"named":384,"of":481,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn only from rows whose own title or URL names the subject (the entity graph's subject gate)"}},"admission":{"state":"canonical","kind":"legacy","kindBasis":"seed","reason":"entity graph provenance 'curated'; part of the hand-written seed vocabulary that predates machine promotion; no receipt exists","policy":"promotion (seed vocabulary; no receipt)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-03-11","to":"2026-10-27","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.081: about 92% of mentions carry no typed assertion"]}},"dimensions":{"domains":["oncology"],"activeDays":177,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":9,"byKind":{"observation":9},"withheld":{"state":"withheld","count":3,"reason":"3 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/63ea2adb300c3900bbc6ce9e","kind":"observation","label":"Targeted Oncology · 2026-10-27 · Olomorasib Combo Shows Manageable Liver Toxicity in KRAS G12C-Mutant NSCLC","url":"https://www.targetedonc.com/view/olomorasib-combination-manageable-liver-toxicity-kras-g12c-mutant-nsclc","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/3f656f9446949d792b867ac6","kind":"observation","label":"STAT News · 2026-10-26 · STAT+: Roche gets a lung cancer win with its KRAS drug divarasib","url":"https://www.statnews.com/2026/10/26/roche-kras-drug-divarasib-lung-cancer-treatment-win/?utm_campaign=rss","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/af1966e584193aed96ed502d","kind":"observation","label":"The Medical News · 2026-10-26 · Next generation KRAS inhibitor divarasib significantly extends lung cancer survival","url":"https://www.news-medical.net/news/20261026/Next-generation-KRAS-inhibitor-divarasib-significantly-extends-lung-cancer-survival.aspx","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/e4ee56e401880099aa69e028","kind":"observation","label":"Crc-Digest · 2026-10-26 · Divarasib Outperforms Existing KRAS G12C Inhibitors in Phase 3 Trial","url":"https://www.targetedonc.com/view/esmo-2026-savolitinib-presidential-symposium-divarasib-nsclc-krascendo1-saffron-clarity-gastric01-harmoni-gi1","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/dcf079752f76daa945a4e576","kind":"observation","label":"PR Newswire · 2026-10-25 · New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer","url":"https://www.prnewswire.com/news-releases/new-data-on-lillys-investigational-treatment-olomorasib-at-esmo-2026-show-durable-first-line-activity-in-kras-g12c-mutant-non-small-cell-lung-cancer-302918479.html","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/27f2e4c4769db7329481d1fb","kind":"observation","label":"OncoDaily · 2026-10-25 · KANDLELIT-001: Calderasib Shows Strong First-Line Activity in KRAS G12C-Mutant NSCLC","url":"https://oncodaily.com/oncolibrary/lung-oncology/kandlelit-001-esmo26","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/702e34e4ee3fce3c2463abac","kind":"observation","label":"N Engl J Med · 2026-10-25 · Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC.","url":"https://doi.org/10.1056/NEJMoa2605703","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/2c9c6d18cbce0fb9656300fb","kind":"observation","label":"Endpoints News · 2026-10-25 · #ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial","url":"https://endpoints.news/esmo26-roche-details-magnitude-of-its-kras-g12c-inhibitors-win-over-rivals-in-lung-cancer-trial/","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}},{"id":"sb:o/ca32e4f7c39b9d2f61aed050","kind":"observation","label":"Medical Xpress · 2026-10-24 · Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study","url":"https://medicalxpress.com/news/2026-10-vaccine-generates-immune-response-kras.html","match":{"surface":"title","basis":"admitted by the entity graph's subject gate (title or URL); the headline names the subject as whole words (the door's on-topic test)"}}],"cursor":null,"order":"newest first; we keep the 9 newest receipts for this entity whose own title or URL (the entity graph's subject gate) names it; each says which in match. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":15,"byKind":{"claim":5,"co-mentioned":10},"items":[{"id":"sb:p/b799b75a09429a35e2aea57d","kind":"claim","label":"STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and more — reported by two","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/23edc8258ddcf0e67305bf57","kind":"claim","label":"New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer — single source","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/50b20e55df14b096b6ea220f","kind":"claim","label":"Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC — could not check","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/08240628bdf41a273ead808d","kind":"claim","label":"Investigational vaccine generates immune response to KRAS mutations in pancreatic cancer study - Mayo Clinic News Network — single source","role":"named-in","relationKind":"claim","members":1},{"id":"sb:p/de86ed2bf7b46b4693e7464d","kind":"claim","label":"Incyte (INCY) Enters KRAS G12D Colon Cancer Trial Collaboration With New Combo Focus - Simply Wall Street — could not check","role":"named-in","relationKind":"claim","members":1},{"kind":"relation","label":"co-mentioned with colorectal cancer (162 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/a2b974f1c240c095cd3e4442"},{"kind":"relation","label":"co-mentioned with lung cancer (114 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1715d936aa939769f1c32a6b"},{"kind":"relation","label":"co-mentioned with g12d (91 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3c25303808c8dcd5bc600407"},{"kind":"relation","label":"co-mentioned with pancreatic cancer (81 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/83d1c9a39c2982651db49395"},{"kind":"relation","label":"co-mentioned with immunotherapy (65 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/2ad88300301226428172cfc9"}],"cursor":"c1.eyJpZCI6InNiOmUvN2UzMzRiNTA3MWU1YjQ0ODYxMDZiMWZkIiwibCI6InJlbGF0aW9ucyIsIm8iOjEwLCJrIjpudWxsLCJhIjoiMjAyNi0xMC0yOVQyMTo1Mjo0MC4yODMzNDIrMDA6MDAifQ","order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/7e334b5071e5b4486106b1fd","mcp":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\"}","page":"/entity/kras/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"free-record","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"free-record","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/7e334b5071e5b4486106b1fd\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"free-record","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history, which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"free-record","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"free-record","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"watch","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"watch","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"watch","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"watch","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"one-time-read","reason":"one-time Reads are not offered through this door; use ask"}]}